Octagon Capital Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Octagon Capital Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,673,750	Closed	-$63.2M	–	65
2023 Q4	$63.2M	Sell	2,673,750 -400,000	-13%	-$7.12M	10.1%	2
2023 Q3	$45.8M	Sell	3,073,750 -1,497,168	-33%	-$19.8M	7.04%	3
2023 Q2	$50.1M	Hold	4,570,918	–	–	6.96%	3
2023 Q1	$39.9M	Buy	4,570,918 +2,711,718	+146%	+$21.7M	5.73%	4
2022 Q4	$11.7M	Buy	+1,859,200	New	+$7.07M	1.82%	14

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Octagon Capital Advisors's CBAY Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 2,673,750 shares — an estimated $63.2M sold.

Octagon Capital Advisors first reported a position in CBAY in Q4 2022 and held it in 5 quarters. The position peaked at $63.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Octagon Capital Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Octagon Capital Advisors sold 2,673,750 Cymabay Therapeutics shares in Q1 2024, an estimated $63.2M.
Octagon Capital Advisors first reported a position in Cymabay Therapeutics in Q4 2022 and held it in 5 quarters.
Octagon Capital Advisors's Cymabay Therapeutics position peaked at $63.2M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.